Aptuit LLC
Two Greenwich Office Park
Greenwich
Connecticut
06831
United States
Tel: 203-422-6600
Fax: 203-422-0266
Website: http://www.aptuit.com/
Email: info@aptuit.com
About Aptuit LLC
Aptuit provides early to mid-phase drug development solutions by applying scientific excellence, outstanding service and a global assembly some of the foremost scientific professionals in the industry. These drug discovery and development professionals offer proven experience in key therapeutic areas. They share a legacy of success, having advanced a large number of molecules efficiently, expeditiously and economically, from early discovery through clinical development with low attrition rates.Aptuit’s provides comprehensive drug development services that are available as a fully integrated offering or on a standalone basis.
These services include: • Drug Design & Discovery • Preclinical Biosciences • API Development & Manufacture • Solid State Chemistry • Pharmaceutical Services • Sterile Fill Finish & Formulation Development • Inhaled and Oral Dosage Form Development & Manufacture • Physical & Analytical Chemistry • Aptuit INDiGO® - fast track to IND program • Integrated Drug Discovery & Development
Aptuit is comprised of a global family of world class facilities that serve more than 600 clients. The client base spans small companies that may not maintain in-house technical expertise to multinational entities that turn to Aptuit for large, integrated products.
Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. This facility combines the proven efficiency of a CRO with the well established scientific expertise of an accomplished and successful Research and Development engine. The breadth of Aptuit Verona’s capabilities bring added value to customers who benefit from the resources of a single site compared to dealing with several suppliers.
Aptuit offers specialized, outstanding services from other facilities in the United States and Europe. Aptuit SSCI in West Lafayette, Indiana is recognized around the world for its solid state chemistry leadership and its outsourcing services. Chief among these are analytical services that employ advanced technology and instrumentation.
Aptuit’s Glasgow, Scotland site has built a notable reputation for the high quality of its sterile fill finish and formulation development for a vast range of dosage forms. Their capabilities include the development of liquid and lyophilized dosage forms, complemented by GMP sterile manufacturing facilities including lyophilized and cytotoxic products.
Aptuit’s dedicated API development and manufacturing facility in Oxford, England has industry-leading competencies in process R&D, analytical and chemical development, preclinical and clinical supply, high potency APIs and cytotoxics, pilot manufacturing and commercial scale manufacturing.
Aptuit’s corporate headquarters are in Greenwich, Connecticut.
The collaborative network of scientists at Aptuit sites provide uncommon expertise that allows Aptuit to identify the unexpected, mitigating risks and maximizing promising possibilities, ensuring exceptional results through an open, transparent climate of trust that our clients can count on.
84 articles about Aptuit LLC
-
Evotec Completes Repayment Of Eur 140 M Acquisition Loan
4/18/2019
Eur 140 m bridge loan was drawn to secure evotec's value chain expansion by successful acquisition of aptuit in august 2017
-
Evotec AG Completes Acquisition Of Aptuit
8/16/2017
-
Evotec AG Pays $300 Million Cash for Aptuit
7/31/2017
-
Aptuit LLC Announces Strategic Provider Agreement With Regulus
6/8/2017
-
Aptuit LLC Announces Alignment Of Organizational Structure To Integrated Solution Delivery: Henning Steinhagen Appointed As President, Research And Development Operations
4/7/2017
-
BioVersys AG And Aptuit LLC Announce Collaboration To Identify Novel Approaches To Treat Serious Infections From Gram-Negative Pathogens
3/7/2017
-
Aptuit LLC Release: Company Announces Drug Discovery Collaboration With Massachusetts General Hospital To Identify Novel Treatments For Gram-Negative Infections
1/24/2017
-
Chronos Therapeutics Partners With Aptuit LLC For Addictive Behaviour Programmes
1/9/2017
-
Aptuit LLC And Chiesi Farmaceutici SpA Initiate Integrated Discovery Project To Identify Novel Compounds For The Treatment Of Idiopathic Pulmonary Fibrosis
1/4/2017
-
Aptuit LLC Announces Enhancement Of Integrated IND Enabling Services
10/13/2016
-
Aptuit LLC And Dimension Therapeutics Enter Strategic Partnership To Advance Select Dimension Programs Toward IND Filing
7/7/2016
-
Aptuit LLC Names Henning Steinhagen As EVP Drug Discovery And Development, And Site-Head Verona
6/1/2016
-
Aptuit LLC Announces Acquisition Of Kuecept Ltd
5/10/2016
-
Aptuit LLC Announces Acquisition Of Exquiron
4/21/2016
-
Aptuit LLC And Icagen, Inc. Agree To Strategic Alliance
2/22/2016
-
Aptuit LLC Announces 16M$ Investment In Capacity And Capability
12/7/2015
-
Aptuit LLC Announces Expansion Of Integrated CMC Offering (Drug Substance And Drug Product) To Phase 3 And Commercial Scale
7/14/2015
-
Aptuit LLC Announces Expansion Of Integrated CMC Offering (Drug Substance And Drug Product) To Phase 3 And Commercial Scale
7/13/2015
-
Aptuit LLC And Axxam SpA Announce Strategic Alliance For Integrated Drug Discovery Services
4/14/2015
-
Aptuit LLC To Divest Two Non-Core Sites; Facilitates Reinvestment And Accelerated Growth In Core Area Of Integrated Solutions
1/9/2015